EU Medical Device Regulation (MDR) Extension (Regulation 2023/607): Impact on Multilingual IFU Timelines
Following the adoption of Regulation (EU) 2023/607 in March 2023 extending MDR transitional periods until 2027/2028, medical device manufacturers must meet strict May 2024 quality management milestones while maintaining multilingual Instructions for Use (IFUs).
Understanding Regulation (EU) 2023/607 Transitional Deadlines
To prevent acute shortages of life-saving medical devices across European hospitals caused by Notified Body capacity bottlenecks, the European Parliament and Council enacted Regulation (EU) 2023/607 on March 20, 2023. The amendment extends the validity of legacy directive certificates (MDD/AIMDD) until December 31, 2027 for higher-risk Class III and Class IIb implantable devices, and until December 31, 2028 for medium- and lower-risk Class IIb, Class IIa, and Class I sterile/measuring devices—subject to strict qualifying conditions.
Why Multilingual Technical Documentation Cannot Wait
Crucially, the extension is not an unconditional pause: manufacturers must implement an MDR-compliant Quality Management System (QMS) and lodge a formal Notified Body application no later than May 26, 2024. Furthermore, Article 10(11) language requirements remain fully enforceable upon MDR certification, requiring Instructions for Use (IFUs), labels, Implant Cards, and Summaries of Safety and Clinical Performance (SSCP) to be translated into up to 24 official EU languages in compliance with ISO 13485 quality workflows.
Executive Takeaways for Global Enterprises
- Key Insight: Regulation (EU) 2023/607 extends MDR transition dates to 2027/2028 only for manufacturers who lodge formal applications by May 2024.
- Key Insight: Post-Market Surveillance (PMS) and vigilance reporting must already comply with MDR standards across all EU markets.
- Key Insight: Early localization of IFUs and SSCPs prevents last-minute commercialization bottlenecks once Notified Body certificates are issued.
Benötigen Sie zertifizierte mehrsprachige Übersetzungen, beglaubigte Fachübersetzungen oder ISO-konforme Lokalisierung für Ihre internationalen Projekte? Fordern Sie ein kostenloses individuelles Angebot von Alphatrad an und erhalten Sie innerhalb von 24 Stunden eine detaillierte Rückmeldung.
Editorial & Copyright Attribution Note: This industry analysis has been independently synthesized and adapted by Alphatrad’s editorial team based on verified regulatory documentation and industry research originally published by Official Journal of the European Union (EUR-Lex). For the original publication and primary documentation, please consult:
Source: https://eur-lex.europa.eu/eli/reg/2023/607/oj
Hinterlassen Sie einen Kommentar
Wollen Sie an der Diskussion teilnehmen?Wir freuen uns über ihren Beitrag!